GSK has announced an agreement to acquire Nuvalent, a clinical-stage biotechnology company focused on precision cancer therapies, in a transaction valued at approximately 10.6 billion USD. The deal significantly strengthens GSK's oncology pipeline and expands its presence in the rapidly growing lung cancer treatment market.
Under the terms of the agreement, GSK will acquire Nuvalent for 124 USD per share in cash, representing a premium of about 40% over Nuvalent's previous closing share price. The acquisition is expected to be completed during the third quarter of 2026, subject to regulatory approvals and customary closing conditions.
Nuvalent brings to GSK a promising portfolio of targeted cancer therapies, including zidesamtinib and neladalkib, two late-stage treatments for non-small cell lung cancer (NSCLC) that are currently under review by the U.S. FDA. Both candidates have the potential to become major commercial products if approved later this year.
GSK stated that the acquisition aligns with its strategy of acquiring innovative medicines with validated targets and strong growth potential. The company expects the deal to contribute to revenue growth from 2027 onward while helping offset future revenue pressures from upcoming patent expirations in its HIV portfolio.
The transaction also marks a major step in GSK's ongoing effort to rebuild its oncology business. Since re-entering the cancer space through a series of acquisitions and partnerships, the company has been steadily expanding its oncology pipeline. The addition of Nuvalent's assets provides GSK with a strong platform in lung cancer, one of the largest and most competitive areas in oncology.
Industry analysts view the acquisition as a strategic move that could accelerate GSK's long-term growth ambitions and strengthen its position against major oncology competitors. The deal is also one of the largest biopharmaceutical transactions announced this year, highlighting continued industry interest in innovative cancer therapies.
